Provided by Tiger Trade Technology Pte. Ltd.

Veracyte

45.81
+1.623.67%
Post-market: 45.80-0.0100-0.02%19:30 EDT
Volume:1.04M
Turnover:47.58M
Market Cap:3.68B
PE:32.85
High:46.09
Open:44.94
Low:44.41
Close:44.19
52wk High:60.91
52wk Low:29.46
Shares:80.39M
Float Shares:78.97M
Volume Ratio:0.68
T/O Rate:1.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.39
EPS(LYR):0.8200
ROE:8.77%
ROA:4.09%
PB:2.65
PE(LYR):55.87

Loading ...

U.S. Stocks on the MOVE-Snowflake, Cboe, Oracle

Reuters
·
Sep 29

US Stocks on the MOVE-Veracyte, Staar Surgical, Corning

Reuters
·
Sep 29

Veracyte announces new findings from Phase III NRG/RTOG 0815 trial

TIPRANKS
·
Sep 29

Veracyte Gains on Data Supporting Use of Prostate Cancer Test to Guide Treatment Decisions

Reuters
·
Sep 29

Veracyte Decipher Prostate Test Predicts Benefit of Adding Hormone Therapy to Radiation in Phase III Trial Analysis

Reuters
·
Sep 29

Phase Iii Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

THOMSON REUTERS
·
Sep 29

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

GlobeNewswire
·
Sep 26

Veracyte Global Chief Commercial Officer John Leite Sells 4,015 Shares for $160,600

Reuters
·
Sep 23

Analysts Have Conflicting Sentiments on These Healthcare Companies: Veracyte (VCYT), IQVIA Holdings (IQV) and Chemed (CHE)

TIPRANKS
·
Sep 17

Veracyte Director Jens Holstein Disposes of USD 204,747 Common Shares

Reuters
·
Sep 17

Veracyte Adds Another Stream to Bladder Franchise, UBS Says

MT Newswires Live
·
Sep 15

Veracyte Price Target Maintained with a $66.00/Share by Freedom Capital Markets

Dow Jones
·
Sep 15

Veracyte Completes Convergent Genomics Acquisition to Expand Urology

TIPRANKS
·
Sep 15

Veracyte Buys Convergent Genomics

MT Newswires Live
·
Sep 15

Veracyte acquires Convergent Genomics for $150M in cash upfront

TIPRANKS
·
Sep 15

Veracyte Acquires Convergent Genomics, Expanding Its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

THOMSON REUTERS
·
Sep 15

Veracyte, - Acquisition Includes $150 Mln Upfront Cash and up to $30 Mln Milestone Payments

THOMSON REUTERS
·
Sep 15

Veracyte, - Expects to Commercialize Initial Uroamp Test in Late 2028

THOMSON REUTERS
·
Sep 15

UBS Adjusts Price Target on Veracyte to $65 From $52, Keeps Buy Rating

MT Newswires Live
·
Sep 09

Veracyte Director Muna Bhanji Disposes of 1,864 Common Shares Worth $80,086.08

Reuters
·
Sep 04